Protease Inhibitors as Antiviral Agents

Abstract

SUMMARY Currently, there are a number of approved antiviral agents for use in the treatment of viral infections. However, many instances exist in which the use of a second antiviral agent would be beneficial because it would allow the option of either an alternative or a combination therapeutic approach. Accordingly, virus-encoded proteases have emerged as new targets for antiviral intervention. Molecular studies have indicated that viral proteases play a critical role in the life cycle of many viruses by effecting the cleavage of high-molecular-weight viral polyprotein precursors to yield functional products or by catalyzing the processing of the structural proteins necessary for assembly and morphogenesis of virus particles. This review summarizes some of the important general features of virus-encoded proteases and highlights new advances and/or specific challenges that are associated with the research and development of viral protease inhibitors. Specifically, the viral proteases encoded by the herpesvirus, retrovirus, hepatitis C virus, and human rhinovirus families are discussed.

Outliers in SAR and QSAR: Is unusual binding mode a possible source of outliers?

“…Picornaviruses, such as the structurally related polioviruses and rhinoviruses, are among the simplest of the animal viruses and are important human pathogens which have been the target of major drug development efforts [41]. Fig.…”

Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir

“…A possible explanation for this finding, which is partially due to the characteristics of our design, is that the proportion of naïve subjects was higher among the patients receiving indinavir than among patients not. A limitation to our analysis is that we have not assessed factors traditionally associated with the efficacy of saquinavir and ritonavir, such as the lack of oral bioavailability [17] and the difficult treatment compliance due to the occurrence of adverse events [18,19], respectively. Moreover, the interval before success was shorter in the group receiving indinavir.…”

Possible mode of action of antiherpetic activities of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro

“…Current chemotherapeutic antiviral drugs have been characterized as having in many cases limited clinical efficacy, suboptimal pharmacokinetics and toxic side effects (Patick and Potts, 1998). In response to this, it is necessary to identify and develop new antiviral agents with different targets from the standard therapy.…”